Company intelligence / Profile preview

Twenty Twenty Therapeutics

South San Francisco, California, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Twenty Twenty Therapeutics develops innovative devices and diagnostics for eye diseases, with a focus on macular degeneration and preventable blindness. Its flagship program, VitreoDx, is an experimental device designed to collect vitreous liquid biopsies incidental to intravitreal injection, aiming to enable earlier detection and better management of eye diseases[1][6]. Initial feasibility studies show high rates of successful sample acquisition and the ability to detect multiple biomarkers, suggesting potential for routine biopsy collection during standard eye care[6].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Verily Life Sciences (Alphabet)Santen

Beyond the preview

Go deeper on Twenty Twenty Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Twenty Twenty Therapeutics.

Explore the full profile